NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 45 filers reported holding NABRIVA THERAPEUTICS PLC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $569,000 | -21.0% | 1,067,664 | 0.0% | 0.01% | -30.0% |
| Q2 2020 | $720,000 | +19.2% | 1,067,664 | +1.7% | 0.02% | -20.0% |
| Q1 2020 | $604,000 | -78.2% | 1,050,000 | -50.0% | 0.02% | -71.6% |
| Q4 2019 | $2,772,000 | -39.7% | 2,100,000 | -8.7% | 0.09% | -51.9% |
| Q3 2019 | $4,600,000 | +18.3% | 2,300,000 | +43.8% | 0.18% | +29.8% |
| Q2 2019 | $3,888,000 | -0.4% | 1,600,000 | 0.0% | 0.14% | -6.6% |
| Q1 2019 | $3,904,000 | +67.1% | 1,600,000 | 0.0% | 0.15% | +37.3% |
| Q4 2018 | $2,336,000 | -51.9% | 1,600,000 | -11.1% | 0.11% | -37.5% |
| Q3 2018 | $4,860,000 | +118.2% | 1,800,000 | +181.2% | 0.18% | +104.7% |
| Q2 2018 | $2,227,000 | -29.2% | 640,000 | +2.4% | 0.09% | -35.8% |
| Q1 2018 | $3,144,000 | -15.9% | 625,000 | 0.0% | 0.13% | -21.2% |
| Q4 2017 | $3,738,000 | -27.0% | 625,000 | 0.0% | 0.17% | -28.0% |
| Q3 2017 | $5,119,000 | -7.0% | 625,000 | +19.0% | 0.24% | -15.1% |
| Q2 2017 | $5,502,000 | – | 525,000 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 191,028 | $462,000 | 0.08% |
| Sterling Investment Advisors, Ltd. | 5,000 | $12,000 | 0.00% |
| IFP Advisors, Inc | 0 | $0 | 0.00% |